Transcriptomic insight into salinomycin mechanisms in breast cancer cell lines: synergistic effects with dasatinib and induction of estrogen receptor β.

Abstract in brief

• The study explores how combining salinomycin and dasatinib enhances anti-cancer effects in breast cancer cells by inducing cell cycle arrest, increasing reactive oxygen species (iROS), and promoting apoptosis, with effects observed through various genomic and proteomic techniques.
• The combination therapy works synergistically either by targeting the Src-STAT3 pathway or by suppressing multiple pathways simultaneously, leading to improved effectiveness over single drug treatments in different breast cancer cell lines and tumor spheroids.
• RNA sequencing and other molecular analyses suggest that this drug combination causes a timed increase in stress and cell cycle arrest, specifically at the G1/S phase, which helps to slow down or stop cancer cell growth more effectively.]